Amphastar Pharmaceuticals, Inc. (AMPH)

NASDAQ: AMPH · IEX Real-Time Price · USD
29.33
-0.88 (-2.91%)
Dec 5, 2022 3:30 PM EST - Market open
-2.91%
Market Cap 1.46B
Revenue (ttm) 484.85M
Net Income (ttm) 77.23M
Shares Out 48.90M
EPS (ttm) 1.50
PE Ratio 19.57
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 127,114
Open 30.12
Previous Close 30.21
Day's Range 29.33 - 30.15
52-Week Range 20.17 - 44.46
Beta 0.74
Analysts Buy
Price Target 38.00 (+29.4%)
Earnings Date Nov 7, 2022

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opio... [Read more]

Industry Pharmaceuticals
IPO Date Jun 25, 2014
CEO Jack Zhang
Employees 1,761
Stock Exchange NASDAQ
Ticker Symbol AMPH
Full Company Profile

Financial Performance

In 2021, AMPH's revenue was $437.77 million, an increase of 25.13% compared to the previous year's $349.85 million. Earnings were $62.12 million, an increase of 4,327.37%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is 38, which is an increase of 29.43% from the latest price.

Price Target
$38
(29.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clin...

1 week ago - Accesswire

Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administrat...

3 weeks ago - Accesswire

Amphastar Pharmaceuticals (AMPH) Q3 Earnings Meet Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Earnings Preview: Amphastar Pharmaceuticals (AMPH) Q3 Earnings Expected to Decline

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 202...

1 month ago - Accesswire

Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

7 Safe Stocks to Rely on When the Market Swerves

Back in August, I made the argument why now's the right time to buy safe stocks. Just over a month later, this continues to be the case.

Other symbols: BSMCMCCPBDGGLPNSSC
2 months ago - InvestorPlace

Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales ...

3 months ago - Accesswire

Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 16, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Appli...

3 months ago - Accesswire

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 5.41% and 4.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill

Amphastar and Syndax, two top-rated biotech stocks, topped second-quarter estimates on Tuesday. But shares stayed flat.

Other symbols: SNDX
3 months ago - Investors Business Daily

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022

Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Co...

3 months ago - Accesswire

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, aft...

4 months ago - Accesswire

Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings

Amphastar Pharmaceutcls is near a buy zone with earnings due on or around Aug. 9. The post Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings appeared first on Investor's Business...

4 months ago - Investors Business Daily

Stocks To Watch Ahead Of Earnings: Amphastar Pharmaceutcls

Amphastar Pharmaceutcls is near a buy zone with earnings due on or around Aug. 9. The post Stocks To Watch Ahead Of Earnings: Amphastar Pharmaceutcls appeared first on Investor's Business Daily.

4 months ago - Investors Business Daily

Amphastar Receives FDA Approval for Vasopressin

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New ...

4 months ago - Accesswire

Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate Communicatio...

5 months ago - Accesswire

Amphastar Receives FDA Approval for Regadenoson

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New D...

6 months ago - Accesswire

Has Amphastar Pharmaceuticals (AMPH) Outpaced Other Medical Stocks This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

6 months ago - Zacks Investment Research

Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022

Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Comp...

6 months ago - Accesswire

Is a Surprise Coming for Amphastar Pharmaceuticals (AMPH) This Earnings Season?

Amphastar Pharmaceuticals (AMPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

7 months ago - Zacks Investment Research

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after ...

7 months ago - Accesswire

Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Can Amphastar (AMPH) Keep the Earnings Surprise Streak Alive?

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

7 months ago - Zacks Investment Research